AMGN vs IBRX · P/E 24, rev $10.05B vs rev $51.2M
Amgen Inc (AMGN) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the AMGN and IBRX stock pages for the full models.
Not investment advice.